Intrepid Labs推出利用人工智能和自主实验室革新药物配方-动脉网

Intrepid Labs Launches to Transform Drug Formulation with AI and Autonomous Labs

PHARMA FOCUS ASIA 等信源发布 2025-05-13 03:16



可切换为仅中文







Intrepid Labs, a biotechnology company transforming drug formulation development through the use of artificial intelligence (AI) and robotics, emerged from stealth today to accelerate therapeutics development through effective formulations that improve clinical performance.

Intrepid Labs是一家通过使用人工智能（AI）和机器人技术来变革药物配方开发的生物技术公司，今天结束了隐秘模式，通过有效的配方加速治疗药物的开发，从而提升临床效果。

The company has secured several industry partners, and recently closed a $7 million USD seed round led by AVANT BIO, which follows a $4 million USD unannounced pre-seed round led by Radical Ventures, with participation from Propagator Ventures. The proceeds from these financings will expand Intrepid Labs’ team, accelerate the development of its proprietary delivery technologies, and scale commercial operations to keep pace with customer demand..

该公司已经确保了多个行业合作伙伴，并且最近由AVANT BIO领投完成了700万美元的种子轮融资，此前还有由Radical Ventures领投、Propagator Ventures参投的400万美元未公开的预种子轮融资。这些融资所得将用于扩大Intrepid Labs的团队，加速其专有递送技术的开发，并扩展商业运营以满足客户需求。

'It is apparent that traditional approaches to drug formulation aren't working,' said Christine Allen, co-founder and chief executive officer of Intrepid Labs. 'Pharma companies are relying on legacy approaches that fail to deliver the best possible formulations into the clinic. I believe this contributes to the high rate of failure during clinical development.

“显然，传统的药物配方方法并不奏效，”Intrepid Labs的联合创始人兼首席执行官克里斯汀·艾伦表示。“制药公司依赖于未能在临床中提供最佳配方的传统方法。我认为这导致了临床开发过程中的高失败率。”

Intrepid Labs is addressing this overlooked bottleneck in drug development with its transformative approach that unlocks a faster, more precise path to improve the quality of therapeutics. We’re going to change the way the industry thinks about drug formulation.'.

Intrepid Labs 通过其变革性方法解决了药物开发中被忽视的瓶颈问题，这种方法开启了一条更快、更精准的路径来提升治疗药物的质量。我们将改变行业对药物配方的思考方式。

Formulation is a critical step in drug development. Effective formulations not only improve therapeutic efficacy, but also mitigate adverse effects, enhancing overall patient safety, while improving drug development success rates.

配方是药物开发中的关键步骤。有效的配方不仅提高治疗效果，还减轻副作用，提升整体患者安全性，同时提高药物开发成功率。

The conventional approach to formulation design is slow and expensive. It starts with benchmarks from existing formulations and then proceeds, one parameter at a time, through a trial-and-error exercise. As a result, companies often settle for suboptimal formulations that fail to maximize a drug’s performance, leaving most of the design space untapped..

传统配方设计方法速度慢且成本高。它从现有配方的基准开始，然后通过试错法逐一进行参数调整。结果，公司常常采用未能最大化药物性能的次优配方，导致大部分设计空间未被开发。

Intrepid Labs is transforming drug formulation with its Valiant™ platform – a modular, AI-driven robotic lab that rapidly explores the full formulation design space. Starting with an active pharmaceutical ingredient and a target product profile, Valiant selects, prepares, and analyzes formulations through semi- and fully autonomous workflows, refining multiple parameters in parallel with expert oversight.

Intrepid Labs正在通过其Valiant™平台变革药物配方——这是一个模块化、由人工智能驱动的机器人实验室，能够快速探索完整的配方设计空间。从活性药物成分和目标产品概况出发，Valiant通过半自主和全自主的工作流程选择、制备和分析配方，在专家监督下并行优化多个参数。

What once took months can now be achieved in days – delivering optimized formulations through a comprehensive, data-driven process..

过去需要数月才能完成的工作，现在通过全面的数据驱动流程，可以在几天内实现优化配方的交付。

Since its founding in 2023, Intrepid Labs has forged partnerships with multiple drug developers, including some of the largest global pharmaceutical companies, as well as contract research organizations, and small and mid-sized biotechs. Industry partners use the Valiant platform to identify optimized formulations and accelerate drug development.

自 2023 年成立以来，Intrepid Labs 已与多家药物开发商建立了合作关系，其中包括一些全球最大的制药公司、合同研究组织以及中小型生物技术公司。行业合作伙伴使用 Valiant 平台来确定优化的配方并加速药物开发。

At the same time, Intrepid Labs is developing its own proprietary oral and long-acting injectable delivery technologies for small molecules and biologics that are available for licensing..

同时，Intrepid Labs正在开发自己的小分子和生物制品的口服和长效注射递送技术，这些技术可供授权使用。

“Intrepid Labs is unlocking a new era in drug formulation, in which delivery format, dosing frequency, and patient experience can be intentionally designed from day one,” said Sebastien Latapie, partner at AVANT BIO. “By using AI and robotics to screen vast formulation possibilities, its Valiant platform enables more cost-effective therapies and better outcomes for patients.”.

“Intrepid Labs正在开启药物配方的新时代，从第一天起就可以有意设计递送形式、给药频率和患者体验，”AVANT BIO的合伙人塞巴斯蒂安·拉塔皮说道。“通过使用人工智能和机器人技术筛选海量配方可能性，其Valiant平台能够实现更具成本效益的治疗方案，并为患者带来更好的疗效。”

About Intrepid Labs

关于Intrepid Labs

Intrepid Labs was spun out of the University of Toronto to pioneer the use of artificial intelligence and robotics to redefine drug formulation and accelerate therapeutic development. The company is led by CEO and co-founder Dr. Christine Allen, a global expert in drug formulation with over 180 peer-reviewed publications.

Intrepid Labs脱胎于多伦多大学，致力于开创人工智能和机器人技术在药物配方中的应用，重新定义药物研发并加速治疗方法的开发。公司由首席执行官兼联合创始人、全球药物配方专家克里斯汀·艾伦博士领导，她拥有超过180篇同行评审的出版物。

Together with co-founders Dr. Pauric Bannigan (chief scientific officer) and Dr. Riley Hickman (director of research and development), Intrepid’s leadership team leverages expertise in drug delivery, laboratory automation, and AI-driven formulation..

Intrepid的领导团队与联合创始人保罗·班尼根博士（首席科学官）和莱利·希克曼博士（研发总监）一起，利用其在药物输送、实验室自动化和人工智能驱动的配方方面的专业知识。

Intrepid partners with leading pharmaceutical companies, CROs, CDMOs, and biotechs to accelerate research and development (R&D) and enhance formulation strategies. The company is also advancing an internal pipeline of proprietary drug delivery technologies available for licensing. Based in the MaRS Discovery District in Toronto, Intrepid is reshaping how the industry approaches drug formulation R&D.

Intrepid与领先的制药公司、合同研究组织（CRO）、合同开发和生产组织（CDMO）以及生物技术公司合作，加速研发并优化配方策略。该公司还在推进一条内部专有药物递送技术管线，可供授权使用。总部位于多伦多的MaRS发现区，Intrepid正在重塑行业对药物配方研发的处理方式。

Companies with active pharmaceutical ingredients or candidates requiring formulation solutions are encouraged to contact Intrepid at info@intrepidlabs.ai..

拥有活性药物成分或需要制剂解决方案的候选药物公司，鼓励联系 Intrepid，邮箱为 info@intrepidlabs.ai。

Contacts

联系人

Media Contact

媒体联系人

Maggie Williard

玛吉·威利亚德

Account Executive, HDMZ

客户经理，HDMZ

maggie.williard@hdmz.com

(312) 506-5239

Corporate Contact